Tongue Carcinoma

LMSCC16 also harbored two TP53 mutations and showed increased resistance to Cisplatin and Paclitaxel compared to established TSCC cell lines. In contrast, LMSCC16 showed significant modulation of OCT4, increased CCND1 and CCNB1 expression, and reduced CDH1 levels following treatment. We established two novel TSCC cell lines that represent clinically relevant models to explore TSCC carcinogenesis and therapeutic responses, particularly in non-smoking populations.

Both P65 knockdown and miR-302 overexpression dramatically slowed tumor growth in vivo. Our results demonstrate the therapeutic potential of a novel miR-302/P65 axis that limited the progression of TSCC by regulating apoptosis and oncogenic transcription.

Such combined treatment showed promising synergistic interaction via several molecular pathways, which is well tolerated and readily applicable strategy to improve the therapeutic outcome of PDT in cancer cell treatment.

SCC9 and SCC9-CisR cells were treated with Rha alone or in combination with 2-deoxy-D-glucose (2-DG) or sodium lactate (LacNa). Mechanistically, Rha inhibited HIF-1α, thereby attenuating glycolytic flux and decreasing lactate-driven H3K18la. Rha inhibits TSCC progression and enhances cisplatin sensitivity by targeting HIF-1α and repressing the glycolysis/lactate/H3K18la axis, suggesting that Rha is a promising candidate for disrupting metabolic/epigenetic crosstalk in TSCC.

P=N/A, N=33, Recruiting, Centre Hospitalier Universitaire, Amiens | N=14 --> 33 | Trial completion date: Oct 2023 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2026

RhoBTB1 is lowly expressed in TSCC and may inhibit its malignant phenotype by negatively regulating the ROCK1/PTEN/AKT pathway, suggesting its potential as an oncogene and therapeutic target.

In vivo analysis confirmed target engagement (NUDT21-down) and functional restoration (PTEN-, WEE1-, TGF-β-up). This work validates a "post-transcriptional re-engineering" strategy, executed by a logically designed nanoplatform, as a powerful and safe modality for precision gene therapy.

Current evidence does not support Bcl-xL as a general prognostic marker in head and neck squamous cell carcinoma. Nevertheless, Bcl-xL may have prognostic relevance in oral tongue cancer if further studies confirm the original finding.

Molecular findings suggest distinct patterns of TP53 alterations and chromosomal instability in younger patients. The growing burden of OTSCC in young women underscores the need for improved early detection and multi-institutional molecular studies to clarify mechanisms and inform tailored prevention and treatment strategies.

P2, N=24, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027

Delayed diagnosis is common due to low suspicion in "low-risk" individuals. This review underscores NSND OSCC as a unique entity requiring expanded risk assessment, heightened clinical vigilance for persistent oral lesions regardless of habit history, and targeted research into novel prevention and therapeutic strategies.

Mechanistically, DNPEP directly bound to the RACK1 protein, activating the ERK signaling pathway. DNPEP plays a critical role in TSCC progression and cisplatin resistance by interacting with RACK1 and activating ERK signaling, highlighting its potential as a therapeutic target to inhibit TSCC and overcome chemotherapy resistance.